Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease ; volume:11 ; number:1 ; day:21 ; month:3 ; year:2019 ; pages:1-12 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (21.3.2019), 1-12, 12.2019
- Urheber
-
Startin, Carla M.
Ashton, Nicholas J.
Hamburg, Sarah
Hithersay, Rosalyn
Wiseman, Frances K.
Mok, Kin Y.
Hardy, John
Lleó, Alberto
Lovestone, Simon
Parnetti, Lucilla
Zetterberg, Henrik
Hye, Abdul
Strydom, André
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-019-0477-0
- URN
-
urn:nbn:de:101:1-2019050219295311117126
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Startin, Carla M.
- Ashton, Nicholas J.
- Hamburg, Sarah
- Hithersay, Rosalyn
- Wiseman, Frances K.
- Mok, Kin Y.
- Hardy, John
- Lleó, Alberto
- Lovestone, Simon
- Parnetti, Lucilla
- Zetterberg, Henrik
- Hye, Abdul
- Strydom, André
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Melatonin: A potential nighttime guardian against Alzheimer’s
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Melatonin: A potential nighttime guardian against Alzheimer’s
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease